Science News
from research organizations

New evidence on co-prescribing for heart and stroke patients

Date:
April 23, 2010
Source:
University of East Anglia
Summary:
New research shows no risk in combining two commonly-prescribed treatments for patients at risk of heart attacks and strokes.
Share:
         
Total shares:  
FULL STORY

New research by the University of East Anglia (UEA) shows no risk in combining two commonly-prescribed treatments for patients at risk of heart attacks and strokes.

Published this month in the journal Alimentary Pharmacology & Therapeutics, the study is the largest investigation yet into concerns of an adverse interaction between Proton Pump Inhibitors (PPIs) and the antiplatelet drug clopidogrel.

The researchers analysed data from 23 large randomised clinical trials involving more than 90,000 patients worldwide. It concluded that co-prescribing the two drugs caused no adverse effect.

"Recent studies have suggested that patients receiving clopidogrel will not get the full effect of the treatment if they are also taking PPIs," said lead author Dr Yoon Loke, of UEA's School of Medicine. "The aim of our study was to determine the actual effect of the treatment combination on cardiovascular outcomes and mortality.

"Our findings showed no evidence of any effect on overall mortality and no associated risk with the co-prescribing of these agents. It is therefore premature to impose a blanket policy of withdrawal or avoidance of PPI use in patients taking clopidogrel. Clinicians should instead re-focus on a patient's susceptibility to gastric bleeding and not lose sight of the fact that some patients with high gastrointestinal risk may genuinely benefit from PPI therapy."

Patients at risk of heart attack or stroke are routinely prescribed antiplatelet therapy to prevent harmful blood clots. Although the effectiveness of this treatment is well-documented, it can cause bleeding in the stomach, which is potentially life-threatening. Co-prescribing PPIs substantially decreases this risk.

The findings of this new meta-analysis by UEA are in direct contrast to the ongoing safety review by the US Food and Drug Administration (FDA), which has advised health professionals to avoid the concomitant use of clopidogrel and omeprazole (a PPI).

However, the FDA's findings are based on laboratory data rather than a thorough review of actual clinical outcomes in patients.

In the United Kingdom, around 100,000 patients are admitted to hospital each year with heart attack or stroke. In the United States, more than 1.5 million people per year are affected. Patients are typically treated with aspirin and/or clopidogrel, which may cause side effects such as stomach ulcers and bleeding. Proton pump inhibitors are used to prevent gastrointestinal bleeding, and these are one of the most commonly-prescribed classes of drug in the world, costing £425m in England and £7bn globally in 2006.


Story Source:

The above story is based on materials provided by University of East Anglia. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. S. Kwok, Y. K. Loke. Meta-analysis: effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel. Alimentary Pharmacology & Therapeutics, 2010; DOI: 10.1111/j.1365-2036.2010.04247.x

Cite This Page:

University of East Anglia. "New evidence on co-prescribing for heart and stroke patients." ScienceDaily. ScienceDaily, 23 April 2010. <www.sciencedaily.com/releases/2010/04/100408105156.htm>.
University of East Anglia. (2010, April 23). New evidence on co-prescribing for heart and stroke patients. ScienceDaily. Retrieved April 28, 2015 from www.sciencedaily.com/releases/2010/04/100408105156.htm
University of East Anglia. "New evidence on co-prescribing for heart and stroke patients." ScienceDaily. www.sciencedaily.com/releases/2010/04/100408105156.htm (accessed April 28, 2015).

Share This Page:


Recommended Content
 


Health & Medicine News
April 28, 2015

Latest Headlines
updated 12:56 pm ET